ESPERITE (ESP) announces listing measure by Euronext due to delay in publication of its 2018 annual report (as announced on 30 April 2019)
Amsterdam, The Netherlands – 19 May 2019
read more
Esperite N.V. (ESP) : Update to the market on the publication of the Annual Report 2018 and The Cell Factory current configuration.
Amsterdam, The Netherlands – 13 May 2019
read more
Esperite N.V. (ESP) : Update to the market on the publication of the Annual Report 2018.
Amsterdam, The Netherlands – 30 April 2019
read more
ESPERITE (ESP) announces private placement of convertible loan notes to the European Select Growth Opportunities Fund
Amsterdam, The Netherlands – 05 April 2019
read more
CF-MEV-132 drug candidate belongs to the CF-MEV family of anti-inflammatory EV drugs produced by The Cell Factory
Amsterdam, The Netherlands – 27 February 2019
read more
ESPERITE (ESP) announces private placement of convertible loan notes to the European Select Growth Opportunities Fund
Amsterdam, The Netherlands – 26 February 2019
read more
ESPERITE NV (ESP) AND PBKM (FAMICORD GROUP) SIGN EXCLUSIVE AGREEMENT REGARDING POTENTIAL ACQUISITION OF CRYO-SAVE’S FAMILY STEM CELL BANKING BUSINESS.
Amsterdam, the Netherlands – 22 February 2019
read more
ESPERITE (ESP) : European Select Growth Opportunities Fund subscribes to the 24th tranche of investment today
Amsterdam, The Netherlands – 10 January 2019
read more
ESPERITE (ESP) : European Select Growth Opportunities Fund subscribes to the 23rd tranche of investment today
Amsterdam, The Netherlands – 30 November 2018
read more
This investments would put the Company at the pole position on the market with its four Extracellular Vesicles drug candidates for Crohn’s, Bronchopulmonary dysplasia, Epilepsy and Stroke
Amsterdam, The Netherlands – 29 November 2018
read more
